Healthcare provider profile · identity verified

Laura A Rush, D.O.

Family Practice · LOS ANGELES, CA · NPI 1013202738

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	651	229
Lisinopril	Lisinopril	343	113
Rosuvastatin Calcium	Rosuvastatin Calcium	260	94
Losartan Potassium	Losartan Potassium	228	82
Levothyroxine Sodium	Levothyroxine Sodium	181	65
Amlodipine Besylate	Amlodipine Besylate	180	72
Atenolol	Atenolol	175	62
Omeprazole	Omeprazole	171	64
Trazodone Hcl	Trazodone Hcl	167	46
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	162	31
Gabapentin	Gabapentin	137	45
Meloxicam	Meloxicam	136	53
Acyclovir	Acyclovir	135	47
Albuterol Sulfate Hfa	Albuterol Sulfate	133	54
Metformin Hcl Er	Metformin Hcl	123	36
Hydrochlorothiazide	Hydrochlorothiazide	108	31
Metformin Hcl	Metformin Hcl	105	31
Pantoprazole Sodium	Pantoprazole Sodium	102	34
Alendronate Sodium	Alendronate Sodium	92	38
Simvastatin	Simvastatin	87	35
Potassium Chloride	Potassium Chloride	86	31
Carvedilol	Carvedilol	82	25
Metoprolol Tartrate	Metoprolol Tartrate	81	32
Pradaxa	Dabigatran Etexilate Mesylate	79	25
Tamsulosin Hcl	Tamsulosin Hcl	78	26
Clopidogrel	Clopidogrel Bisulfate	74	24
Furosemide	Furosemide	74	30
Glipizide	Glipizide	72	27
Fluoxetine Hcl	Fluoxetine Hcl	71	28
Lorazepam	Lorazepam	71	15
Allopurinol	Allopurinol	70	25
Terazosin Hcl	Terazosin Hcl	70	25
Ibuprofen	Ibuprofen	69	25
Testosterone	Testosterone	69	22
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	67	28
Famotidine	Famotidine	62	22
Alprazolam	Alprazolam	61	19
Sumatriptan Succinate	Sumatriptan Succinate	58	14
Bupropion Xl	Bupropion Hcl	54	21
Jardiance	Empagliflozin	54	19
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	53	18
Montelukast Sodium	Montelukast Sodium	53	18
Tramadol Hcl	Tramadol Hcl	53	16
Fenofibrate	Fenofibrate	51	16
Mirtazapine	Mirtazapine	51	11
Metoprolol Succinate	Metoprolol Succinate	50	11
Doxycycline Monohydrate	Doxycycline Monohydrate	44	23
Finasteride	Finasteride	44	17
Triamcinolone Acetonide	Triamcinolone Acetonide	42	27
Ozempic	Semaglutide	41	suppressed
Duloxetine Hcl	Duloxetine Hcl	40	11
Ezetimibe	Ezetimibe	38	12
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	38	18
Sertraline Hcl	Sertraline Hcl	38	13
Citalopram Hbr	Citalopram Hydrobromide	37	12
Temazepam	Temazepam	37	suppressed
Menveo A-C-Y-W-135-Dip	Mening Vac A,c,y,w-135 Dip/Pf	36	36
Escitalopram Oxalate	Escitalopram Oxalate	35	12
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	33	33
Prednisone	Prednisone	33	32
Venlafaxine Hcl Er	Venlafaxine Hcl	33	suppressed
Pregabalin	Pregabalin	31	suppressed
Valacyclovir	Valacyclovir Hcl	31	11
Alvesco	Ciclesonide	30	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	30	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	27	12
Paroxetine Hcl	Paroxetine Hcl	26	suppressed
Testosterone Cypionate	Testosterone Cypionate	26	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	25	12
Baclofen	Baclofen	25	suppressed
Azelastine Hcl	Azelastine Hcl	24	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	24	suppressed
Eliquis	Apixaban	24	12
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	23	suppressed
Ropinirole Hcl	Ropinirole Hcl	23	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	22	22
Egrifta Sv	Tesamorelin Acetate	22	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	22	suppressed
Hydralazine Hcl	Hydralazine Hcl	22	suppressed
Naproxen	Naproxen	22	suppressed
Bupropion Hcl Sr	Bupropion Hcl	21	suppressed
Spiriva Respimat	Tiotropium Bromide	21	suppressed
Flunisolide	Flunisolide	20	11
Potassium Citrate Er	Potassium Citrate	20	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	19	19
Fluticasone Propionate	Fluticasone Propionate	19	suppressed
Cefuroxime	Cefuroxime Axetil	18	18
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	18	suppressed
Humulin N	Insulin Nph Human Isophane	18	suppressed
Spironolactone	Spironolactone	18	suppressed
Estradiol	Estradiol	17	suppressed
Pravastatin Sodium	Pravastatin Sodium	17	suppressed
Retin-A	Tretinoin	17	suppressed
Buspirone Hcl	Buspirone Hcl	16	suppressed
Clonazepam	Clonazepam	16	suppressed
Colchicine	Colchicine	16	suppressed
Lovastatin	Lovastatin	16	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	15	15
Ondansetron Hcl	Ondansetron Hcl	15	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	15	suppressed
Propranolol Hcl	Propranolol Hcl	15	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	15	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	15	suppressed
Amoxicillin	Amoxicillin	14	suppressed
Chlorthalidone	Chlorthalidone	14	suppressed
Glipizide-Metformin	Glipizide/Metformin Hcl	14	suppressed
Ciclopirox	Ciclopirox	13	suppressed
Donepezil Hcl	Donepezil Hcl	13	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	13	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	13	suppressed
Brilinta	Ticagrelor	12	suppressed
Humalog Kwikpen U-100	Insulin Lispro	12	suppressed
Benazepril Hcl	Benazepril Hcl	11	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	11	suppressed
Ketoconazole	Ketoconazole	11	suppressed
Ondansetron Odt	Ondansetron	11	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	11	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	11	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error